Journal of Investigative Medicine High Impact Case Reports (Feb 2017)

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia

  • Mayur D. Mody MD,
  • Deepak Ravindranathan MD,
  • Harpaul S. Gill MD,
  • Vamsi K. Kota MD

DOI
https://doi.org/10.1177/2324709617690747
Journal volume & issue
Vol. 5

Abstract

Read online

Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.